Search results
GSK Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 5 days agoWe expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
Zacks via Yahoo Finance· 1 year agoGSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive...
GSK's Key Drugs to Drive Sales in a Sluggish Second Half
Zacks via Yahoo Finance· 2 years agoGSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up...
GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance
Zacks via Yahoo Finance· 9 months agoGSK's revenues benefit from strong growth across all segments, especially HIV and vaccine. GSK...
GSK Gears Up to Report Q4 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 1 year agoGSK plc. GSK will report fourth-quarter 2022 results on Feb 1, before the opening bell. In the last...
GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up
Zacks via Yahoo Finance· 1 year agoGSK plc GSK reported third-quarter 2022 adjusted earnings of $1.09 per American depositary share...
GSK Clocks 10% Growth In Q1 Sales Excluding COVID-19 Products, Reaffirms Guidance
Benzinga via Yahoo Finance· 1 year agoGSK plc (NYSE: GSK) reported Q1 FY23 sales of £6.95 billion, down 3% Y/Y on the actual exchange rate...
GSK Outperforms Industry on Strength in Key Drugs & Vaccines
Zacks via Yahoo Finance· 1 month agoStrong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and...
GSK Key Drugs & Vaccines Help Stock Outperform Industry YTD
Zacks via Yahoo Finance· 5 months agoStrong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and...
GSK strikes £1.1bn deal for asthma drugmaker
The Telegraph via Yahoo Finance· 4 months agoIt is hoped the treatment that's been purchased by GSK will help patients cut down on the use of inhalers - bymuratdeniz GSK has bought a drug to treat...